CPT Encapsulated Silica-titania Hollow Nanoparticle Targeting SK-BR-3 Cells for efficient Anticancer treatment. Issue 1725 (24th February 2015)

• Record Type: Journal Article
• Authors: Jang, Yoonsun; Jang, Jyongsik
• Editors: Ajayan, P.M.; Koester, S.J.; McDevitt, M.R.; Renugopalakrishnan, V.
• Is Part Of: MRS proceedings. Issue 1725:(2015)
• Publication Date: 2015-02-24
• Subjects: biomedical, -- nanostructure, -- nanoscale; Electrical engineering -- Congresses; Physics -- Congresses; Materials -- Research -- Congresses; Materials science -- Congresses; 620.11
• DOI: 10.1557/opl.2015.166
• Languages: English
• ISSNs: 0272-9172

Abstract

ABSTRACT: HER-conjugated hollow nanoparticles (HER–HNP, ca. 50 nm in diameter) are fabricated using a dissolution and re-deposition method and used to encapsulate camptothecin (CPT). The HER-HNP-CPT is used as an anti-cancer agent for human breast cancer SK-BR-3. It has excellent mono-dispersity and a high loading efficiency for CPT. Two kind of cell lines are used in this study; SK-BR-3 and RAW 264.7. SK-BR-3 and RAW 264.7 are used as targeting and controlling cell line, respectively. When SK-BR-3 cells are treated with HER-HNP-CPT, the viability decreased to 55%, which is ca. 1.5 times higher anti-cancer efficiency in comparison to RAW 264.7. The HER-HNP-CPT system offers a new opportunity to facilitate implementation of a hydrophobic drug for effective anti-cancer treatment of SK-BR-3 cells.